Payment overview · 2025
General Payments
$706.20
36 reported records · 9 companies
Healthcare provider profile · identity verified
John David Stack, PA
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · OROVILLE, CA · NPI 1629170592
Verified facts
What the public records show
CMS Open Payments records show John David Stack, PA received $706.20 in general payments during 2025 across 36 reported records.
ABBVIE INC. accounted for 41.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Rybelsus, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 188 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 188 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $293.59 | 41.6% | 17 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $90.98 | 12.9% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $79.54 | 11.3% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $72.47 | 10.3% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $55.63 | 7.9% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $44.04 | 6.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $37.23 | 5.3% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.36 | 2.6% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $14.36 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $706.20 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $174.14 | 10 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $152.83 | 8 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $79.54 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $75.58 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $63.81 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $63.81 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $62.40 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $49.76 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $43.87 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $37.23 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $37.23 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $27.17 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $22.71 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $22.71 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $20.82 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $19.01 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $14.36 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 188 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 73 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 78 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 140 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
188 | 49 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
140 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
188 | 49 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
103 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
73 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
78 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 355 | 98 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 329 | 88 |
| Levothyroxine Sodium | Levothyroxine Sodium | 271 | 60 |
| Lisinopril | Lisinopril | 257 | 78 |
| Gabapentin | Gabapentin | 221 | 64 |
| Metoprolol Tartrate | Metoprolol Tartrate | 216 | 70 |
| Omeprazole | Omeprazole | 192 | 66 |
| Jardiance | Empagliflozin | 188 | 49 |
| Metformin Hcl | Metformin Hcl | 166 | 44 |
| Amlodipine Besylate | Amlodipine Besylate | 154 | 42 |
| Potassium Chloride | Potassium Chloride | 148 | 51 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 140 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 116 | 41 |
| Buspirone Hcl | Buspirone Hcl | 112 | 40 |
| Trulicity | Dulaglutide | 103 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 102 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 99 | 31 |
| Losartan Potassium | Losartan Potassium | 97 | 32 |
| Quetiapine Fumarate | Quetiapine Fumarate | 95 | 25 |
| Alendronate Sodium | Alendronate Sodium | 90 | 29 |
| Furosemide | Furosemide | 90 | 27 |
| Glipizide | Glipizide | 85 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 79 | 12 |
| Rybelsus | Semaglutide | 78 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 74 | 20 |
| Ozempic | Semaglutide | 73 | 16 |
| Montelukast Sodium | Montelukast Sodium | 68 | 22 |
| Januvia | Sitagliptin Phosphate | 66 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 65 | 21 |
| Eliquis | Apixaban | 62 | 16 |
| Sertraline Hcl | Sertraline Hcl | 61 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 57 | 17 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 56 | 12 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 54 | 42 |
| Ibuprofen | Ibuprofen | 54 | 19 |
| Allopurinol | Allopurinol | 53 | 16 |
| Pregabalin | Pregabalin | 53 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 50 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 50 | 34 |
| Azelastine Hcl | Azelastine Hcl | 45 | 27 |
| Tramadol Hcl | Tramadol Hcl | 43 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 43 | 14 |
| Trazodone Hcl | Trazodone Hcl | 42 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 37 | 12 |
| Ammonium Lactate | Ammonium Lactate | 36 | 23 |
| Topiramate | Topiramate | 36 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 35 | 12 |
| Vascepa | Icosapent Ethyl | 35 | suppressed |
| Dexamethasone | Dexamethasone | 32 | 28 |
| Mirtazapine | Mirtazapine | 32 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Famotidine | Famotidine | 31 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 16 |
| Ezetimibe | Ezetimibe | 28 | 11 |
| Methocarbamol | Methocarbamol | 28 | suppressed |
| Nystatin | Nystatin | 28 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 27 | suppressed |
| Lorazepam | Lorazepam | 27 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 19 |
| Carvedilol | Carvedilol | 25 | suppressed |
| Estradiol | Estradiol | 25 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 25 | suppressed |
| Naproxen | Naproxen | 25 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | 11 |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 12 |
| Trueplus Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 19 | suppressed |
| Methotrexate | Methotrexate Sodium | 19 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Belsomra | Suvorexant | 18 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Vraylar | Cariprazine Hcl | 17 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Cilostazol | Cilostazol | 15 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 15 | 13 |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Exemestane | Exemestane | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | 11 |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Ssd | Silver Sulfadiazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $706.20 · 36 records | ABBVIE INC. | AREXVY, BREZTRI, CAPLYTA, CREON, FARXIGA, INJECTAFER, JARDIANCE, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Wegovy | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error